These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 11471359)

  • 1. [Critical reflections on innovation, therapeutic progress and economics of health].
    Bouvenot G
    Therapie; 2001; 56(2):103-6. PubMed ID: 11471359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Quantification of pharmacological progress by the French National Health Authorities].
    Bouvenot G
    Bull Acad Natl Med; 2006; 190(4-5):893-903; discussion 903-4. PubMed ID: 17195614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Introduction to pharmaco-economics: 'glossary'].
    Auray JP
    Therapie; 2001; 56(2):89-91. PubMed ID: 11471379
    [No Abstract]   [Full Text] [Related]  

  • 5. Should health care come with a warranty?
    de Brantes F; D'Andrea G; Rosenthal MB
    Health Aff (Millwood); 2009; 28(4):w678-87. PubMed ID: 19531556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative added value: what are the tools to evaluate it?
    Le Jeunne C; Woronoff-Lemsi MC; David N; de Sahb R;
    Therapie; 2008; 63(2):113-7, 107-11. PubMed ID: 18561884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Costs and benefits in health care--in search of a correct assessment].
    Selbmann HK
    Dtsch Med Wochenschr; 2008 Dec; 133(49):2579-81. PubMed ID: 19039714
    [No Abstract]   [Full Text] [Related]  

  • 8. Why are employers prodding health-care providers to adopt new management systems?: reducing the cost of health care.
    De Feo JA
    Clin Leadersh Manag Rev; 2004; 18(2):80-5. PubMed ID: 15085703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Quality in health care. What quality? Judged by which criteria? By whom? How?].
    Bergmann JF; Mahé I
    Therapie; 2001; 56(2):99-102. PubMed ID: 11471381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Economics, health, and health care].
    Lema Devesa MC
    Neurologia; 2003 Dec; 18 Suppl 4():57-63. PubMed ID: 15206332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of essential drugs. Sixth report of the WHO Expert Committee.
    World Health Organ Tech Rep Ser; 1995; 850():1-137. PubMed ID: 7597816
    [No Abstract]   [Full Text] [Related]  

  • 12. [The origin of informed consent].
    Mallardi V
    Acta Otorhinolaryngol Ital; 2005 Oct; 25(5):312-27. PubMed ID: 16602332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficiency versus quality in the NHS, in Portugal: methodologies for evaluation].
    Giraldes Mdo R
    Acta Med Port; 2008; 21(5):397-410. PubMed ID: 19187682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prevention of avoidable iatrogenic disease: when patient safety joins with health care economics].
    Queneau P; Bergmann JF
    Therapie; 2001; 56(2):163-8. PubMed ID: 11471369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical industry overview: optimal drug therapy.
    Blake P
    Can J Clin Pharmacol; 2001; 8 Suppl A():48A-52A. PubMed ID: 11586380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baby doe redux? The Department of Health and Human Services and the Born-Alive Infants Protection Act of 2002: a cautionary note on normative neonatal practice.
    Sayeed SA
    Pediatrics; 2005 Oct; 116(4):e576-85. PubMed ID: 16199687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model for improvement - Part 1: A framework for health care quality.
    Courtlandt CD; Noonan L; Feld LG
    Pediatr Clin North Am; 2009 Aug; 56(4):757-78. PubMed ID: 19660626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Access to medicines in France].
    Bouvenot G; Bouvenot J
    Bull Acad Natl Med; 2009 Mar; 193(3):649-59; discussion 659-62. PubMed ID: 19883016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of formularies on clinical innovation.
    Goodwin FK
    J Clin Psychiatry; 2003; 64 Suppl 17():11-4. PubMed ID: 14680421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.